Navigation Links
GMSbiotech and Pure Transplant Solutions Announce Strategic Collaboration
Date:11/18/2013

Inverness, Ill and Oklahoma City, OK (PRWEB) November 18, 2013

GMSbiotech, Inc. (GMS), creator of novel microarray-based diagnostic solutions for personalized medicine and transplantation compatibility and Pure Transplant Solutions, LLC, (PTS) a leader in soluble HLA reagents production and application development, today announced a partnership that will leverage the GMS platform and the PTS soluble HLA technology including its suite of over 200 Class I and Class II alleles, anticipated to grow to 300 alleles over the duration of the project.

"We have invested over $15M in the last 14 years to develop the PTS reagent technology and GMS has invested over $10M in the last 10 years developing their platform," said Thomas Harlan, CEO Pure Transplant Solutions, "Leveraging our combined infrastructures and unique strengths will allow us to develop a novel technology solution while lowering the risk, time and costs normally associated with these types of ventures."

"We are excited about this collaboration and look forward to the development of a prototype which we hope to distribute by Q3 2014 to select ASHI certified labs for beta testing," said Dr. Krishna Jayaraman, President & CEO of GMSbiotech.

About GMSbiotech, Inc.

GMSbiotech (GMS) is a privately held company focusing on its patented microarray platform to develop accurate and affordable genetic and serology tests. With the company’s disruptive technology in Raw Sample Genotyping (RSG) combined with its microarray platform, complex genetic testing experienced by labs across the field has been substantially simplified into a routine, everyday low-cost component of clinical diagnostics and public health screening. The company is commercializing its technologies with an initial focus on transplantation diagnostics. For additional information on the company please visit http://www.gmsbiotech.com.

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, L.L.C. ("PTS") is a subsidiary of Pure Protein L.L.C, a company that has developed and patented several soluble HLA protein technology methods and immunology tools for therapeutic and diagnostic applications in solid organ and stem cell transplantation, cross-reactive antibody screening, and major autoimmune diseases. Pure Protein was formed in 1999 to commercialize research developed by Dr. William Hildebrand at the University of Oklahoma Health Sciences Center. Pure Transplant Solutions was formed in 2003 to use HLA protein to develop diagnostics, devices, and therapeutics to help eliminate transplant rejection. To learn more visit http://www.pureproteinllc.com.

Pure Protein and its subsidiaries are funded and managed by innovation solutions company Emergent Technologies, Inc. For more information visit http://www.emergenttechnolgogies.com.

Read the full story at http://www.prweb.com/releases/2013/11/prweb11341302.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Case Report Published in the Journal Perfusion on 14-Year-Old Pediatric Patient Bridged to Transplant with SynCardia Total Artificial Heart
2. Adaptive Biotechnologies Receives $2.53 million Phase II SBIR to Develop Test to Identify Cancer Patients at Risk of Death by Infection after Cord Blood Transplants
3. UK’s 1st SynCardia Total Artificial Heart Patient Bridged to Transplant at Papworth Hospital
4. OrganJet customer receives kidney transplant years faster due to smart multiple listing
5. Pure Transplant Solutions Launches Crowdfunding Campaign for Its Novel Technology Poised to Change the Future of Organ Transplantation
6. SynCardia Total Artificial Heart Bridges Mother of Four with Congenital Heart Defect & Biventricular Heart Failure to Transplant
7. Universal Stem Cell Product Could Overcome Key Challenges in Donor Organ Transplants
8. SynCardia Total Artificial Heart Bridges Former Semi-Pro Arena Football Player to Heart Transplant
9. Researchers identify signals that direct the immune system to reject a transplanted organ
10. Stem cell transplant restores memory, learning in mice
11. Stem cells produce compact, regenerated bone in mandible transplants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... the trading session at 4,833.32, down 0.22%; the Dow Jones ... the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ... BIND Therapeutics Inc. (NASDAQ: BIND ). Learn more ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... line of intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining ... Chicago. The result of a collaboration among several companies with expertise in toolholding, ...
(Date:6/22/2016)... , June 22, 2016 Cell Applications, ... allow them to produce up to one billion ... lot within one week. These high-quality, consistent stem ... preparing cells and spend more time doing meaningful, ... a proprietary, high-volume manufacturing process that produces affordable, ...
Breaking Biology Technology:
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
Breaking Biology News(10 mins):